Morgan Stanley on Ultragenyx Pharma (RARE): BLA submission acceptance removes key overhang
Tweet Send to a Friend
Morgan Stanley analyst Maxwell Skor reiterated an Overweight rating and $50.00 price target on Ultragenyx Pharma (NASDAQ: RARE)The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
